ATE164313T1 - Inaktivierte respiratorische synzytial-virus- impfstoffe - Google Patents

Inaktivierte respiratorische synzytial-virus- impfstoffe

Info

Publication number: ATE164313T1
Authority: AT; Austria
Prior art keywords: virus; inactivated; immunogenic composition; purified; synzytial
Prior art date: 1993-08-06

Application number

AT94923619T

Other languages

English (en)

Inventor

Sonia E Sanhueza

Mary Elizabeth Ewasyshyn

Michel Henri Klein

Original Assignee

Connaught Lab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-08-06

Filing date

1994-08-04

Publication date

1998-04-15

1994-08-04 Application filed by Connaught Lab filed Critical Connaught Lab

1998-04-15 Application granted granted Critical

1998-04-15 Publication of ATE164313T1 publication Critical patent/ATE164313T1/de

Links

241000700605 Viruses Species 0.000 title abstract 6
229960005486 vaccine Drugs 0.000 title abstract 3
230000000241 respiratory effect Effects 0.000 title abstract 2
230000002163 immunogen Effects 0.000 abstract 4
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract 2
230000001413 cellular effect Effects 0.000 abstract 2
210000002966 serum Anatomy 0.000 abstract 2
229960005070 ascorbic acid Drugs 0.000 abstract 1
235000010323 ascorbic acid Nutrition 0.000 abstract 1
239000011668 ascorbic acid Substances 0.000 abstract 1
VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 abstract 1
239000003599 detergent Substances 0.000 abstract 1
230000028993 immune response Effects 0.000 abstract 1
230000002434 immunopotentiative effect Effects 0.000 abstract 1
238000001727 in vivo Methods 0.000 abstract 1
208000015181 infectious disease Diseases 0.000 abstract 1
230000002458 infectious effect Effects 0.000 abstract 1
HEGSGKPQLMEBJL-UHFFFAOYSA-N n-octyl beta-D-glucopyranoside Natural products CCCCCCCCOC1OC(CO)C(O)C(O)C1O HEGSGKPQLMEBJL-UHFFFAOYSA-N 0.000 abstract 1
HEGSGKPQLMEBJL-RGDJUOJXSA-N octyl alpha-D-glucopyranoside Chemical compound CCCCCCCCO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RGDJUOJXSA-N 0.000 abstract 1
HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 abstract 1
229960000380 propiolactone Drugs 0.000 abstract 1
230000001681 protective effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/02—Recovery or purification
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18551—Methods of production or purification of viral material

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Virology (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Microbiology (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biomedical Technology (AREA)
Genetics & Genomics (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Mycology (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Pulmonology (AREA)
General Engineering & Computer Science (AREA)
Cell Biology (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Communicable Diseases (AREA)
Pathology (AREA)
General Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Physics & Mathematics (AREA)
Food Science & Technology (AREA)
Tropical Medicine & Parasitology (AREA)

AT94923619T 1993-08-06 1994-08-04 Inaktivierte respiratorische synzytial-virus- impfstoffe ATE164313T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US10274293A	1993-08-06	1993-08-06

Publications (1)

Publication Number	Publication Date
ATE164313T1 true ATE164313T1 (de)	1998-04-15

Family

ID=22291469

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT94923619T ATE164313T1 (de)	1993-08-06	1994-08-04	Inaktivierte respiratorische synzytial-virus- impfstoffe

Country Status (15)

Country	Link
US (1)	US7083795B1 (de)
EP (1)	EP0714306B1 (de)
JP (1)	JP4053587B2 (de)
KR (1)	KR100402379B1 (de)
CN (1)	CN1103603C (de)
AT (1)	ATE164313T1 (de)
AU (1)	AU677090B2 (de)
BR (1)	BR9407182A (de)
CA (1)	CA2167274C (de)
DE (1)	DE69409243T2 (de)
DK (1)	DK0714306T3 (de)
ES (1)	ES2113670T3 (de)
GR (1)	GR3026619T3 (de)
RU (1)	RU2142817C1 (de)
WO (1)	WO1995004545A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4243491A1 (de) *	1992-12-22	1994-06-23	Behringwerke Ag	Verfahren zur Reinigung und Anreicherung von Rubella-Virus
RU2289425C2 (ru) *	2004-12-09	2006-12-20	Михаил Петрович Костинов	Способ профилактики заболеваний лор-органов и органов дыхательной системы, обусловленных вирусной и неспецифической бактериальной флорой у детей раннего возраста, рожденных от вич-инфицированных матерей
CN106008716B (zh) *	2010-07-07	2019-08-13	人工细胞科技公司	呼吸道合胞病毒抗原组合物和方法
DK3728287T3 (da) *	2017-12-19	2024-06-10	CSL Behring Lengnau AG	Proteinoprensning og virusinaktivering med alkylglycosider
JP7614841B2 (ja)	2018-04-03	2025-01-16	サノフイ	抗原性呼吸器合胞体ウイルスポリペプチド
CN110684747B (zh) *	2018-07-06	2024-05-24	厦门大学	灭活及保存呼吸道合胞病毒的方法
CN114828885A (zh) *	2019-12-10	2022-07-29	瑞普利金公司	制备病毒载体的方法
EP4281065A1 (de)	2021-01-20	2023-11-29	Alto Neuroscience, Inc.	Verbesserung der camp-signalisierung als kombinationsarzneimittelstrategie zur behandlung von depression und verwandten erkrankungen

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1188985A (en) *	1980-07-01	1985-06-18	National Research Development Corporation	Production of viral antigens
US4591505A (en) *	1982-04-14	1986-05-27	New York Blood Center, Inc.	Process for inactivating hepatitis B virus
US4664912A (en)	1984-10-01	1987-05-12	Wiktor Tadeusz J	Process for the large scale production of rabies vaccine
US4790987A (en) *	1985-11-15	1988-12-13	Research Corporation	Viral glycoprotein subunit vaccine
US4732683A (en) *	1986-12-02	1988-03-22	Biospectrum, Inc.	Purification method for alpha interferon
DE3886332T2 (de) *	1987-09-28	1994-03-31	Beecham Inc	Inaktivierung von Viren und Bakterien.
US5200179A (en) *	1987-09-28	1993-04-06	Beecham Group P.L.C.	Vaccine
US5223254A (en) *	1987-09-29	1993-06-29	Praxis Biologics, Inc.	Respiratory syncytial virus: vaccines
GB8914968D0 (en)	1989-06-29	1989-08-23	Connaught Lab	Production of virus and purification of viral envelope proteins for vaccine use
TW275632B (de) *	1992-04-21	1996-05-11	American Cyanamid Co
IL105456A (en)	1992-04-21	1996-12-05	American Home Prod	Vaccines of attenuated respiratory syncytial virus

1994
- 1994-08-04 RU RU96105905A patent/RU2142817C1/ru not_active IP Right Cessation
- 1994-08-04 KR KR1019960700607A patent/KR100402379B1/ko not_active Expired - Fee Related
- 1994-08-04 BR BR9407182A patent/BR9407182A/pt not_active Application Discontinuation
- 1994-08-04 AT AT94923619T patent/ATE164313T1/de active
- 1994-08-04 AU AU73801/94A patent/AU677090B2/en not_active Ceased
- 1994-08-04 ES ES94923619T patent/ES2113670T3/es not_active Expired - Lifetime
- 1994-08-04 CA CA002167274A patent/CA2167274C/en not_active Expired - Fee Related
- 1994-08-04 US US08/583,124 patent/US7083795B1/en not_active Expired - Fee Related
- 1994-08-04 EP EP94923619A patent/EP0714306B1/de not_active Expired - Lifetime
- 1994-08-04 CN CN94193703A patent/CN1103603C/zh not_active Expired - Lifetime
- 1994-08-04 WO PCT/CA1994/000425 patent/WO1995004545A1/en not_active Ceased
- 1994-08-04 DE DE69409243T patent/DE69409243T2/de not_active Expired - Lifetime
- 1994-08-04 JP JP50612395A patent/JP4053587B2/ja not_active Expired - Fee Related
- 1994-08-04 DK DK94923619T patent/DK0714306T3/da active
1998
- 1998-04-10 GR GR980400815T patent/GR3026619T3/el unknown

Also Published As

Publication number	Publication date
EP0714306A1 (de)	1996-06-05
DE69409243D1 (de)	1998-04-30
RU2142817C1 (ru)	1999-12-20
CA2167274A1 (en)	1995-02-16
EP0714306B1 (de)	1998-03-25
DK0714306T3 (da)	1998-10-19
ES2113670T3 (es)	1998-05-01
AU677090B2 (en)	1997-04-10
DE69409243T2 (de)	1998-08-06
BR9407182A (pt)	1996-09-17
CA2167274C (en)	2007-11-27
GR3026619T3 (en)	1998-07-31
JP4053587B2 (ja)	2008-02-27
AU7380194A (en)	1995-02-28
CN1103603C (zh)	2003-03-26
US7083795B1 (en)	2006-08-01
JPH09501912A (ja)	1997-02-25
KR100402379B1 (ko)	2004-03-24
KR960703618A (ko)	1996-08-31
CN1133013A (zh)	1996-10-09
WO1995004545A1 (en)	1995-02-16

Legal Events

Date	Code	Title	Description
1998-11-15	UEP	Publication of translation of european patent specification

Publication	Publication Date	Title
WO2005116270A3 (en)	2007-12-21	Influenza virus vaccine composition and method of use
BR9510263A (pt)	1997-11-04	Novo derivado de ciclodextrina processo para sua preparação utilização dos mesmos composição terapêutica e adjuvante para vacinas
CA2121241A1 (en)	1993-04-29	Porcine reproductive respiratory syndrome vaccine and diagnostic
WO2004001007A3 (en)	2004-07-01	Buffered formulations for concentrating antibodies and methods of use thereof
DK0777490T3 (da)	2006-09-18	Mutant-enterotoxin, som er effektivt som et ikke-toksisk oralt adjuvans
MX9306841A (es)	1995-01-31	Vacuna a base de ureasa contra la infeccion por helicobacter en mamiferos.
HU229368B1 (en)	2013-11-28	Novel vaccine composition
NO964413L (no)	1996-12-17	Gruppe A streptokokkisk polysakkarid, immunogene blandinger derav samt anvendelse derav
FI905184A0 (fi)	1990-10-19	Kimeriska glykoproteiner som innehaoller immunogeniska delar av human parainfluensa-virus typ 3.
ATE164313T1 (de)	1998-04-15	Inaktivierte respiratorische synzytial-virus- impfstoffe
SE8005824L (sv)	1980-08-19	Vaccin av hudparvovirus samt forfarande for dess framstellning
DE69940406D1 (de)	2009-03-26	Ine rsv untereinheit zusammensetzung und ein influenzavirus präparat enthält
EP0480949A1 (de)	1992-04-22	Herstellung eines virus und reinigung von virenüberzugsproteinen zur impfstoffverwendung.
ES379641A1 (es)	1972-08-01	Procedimiento de produccion de antigenos inactivos para preparados farmaceuticos.
ATE354370T1 (de)	2007-03-15	Inaktivierte immunogene bakterielle ganzzell- zusammensetzungen
DE68923169D1 (de)	1995-07-27	Verwendung von fluor enthaltenden Pyridoncarbonsäure-Derivaten zur Herstellung eines Arzneimittels zur Behandlung von HIV infektionen.
WO1999053950A3 (en)	2000-01-13	Live vaccines and methods of treatment therewith
NO169820C (no)	1992-08-12	Fremgangsmaate for fremstilling av en mastittvaksine
HUP9700975A2 (hu)	1998-05-28	Élő, legyengített, Pasteurellaceae családba tartozó, RTX-termelő baktériumok
JPS6456620A (en)	1989-03-03	Production of hemorrhagic fever with renal syndrome virus antigen and vaccine and diagnostic agent using said antigen
AU8778582A (en)	1983-03-10	Polymerized albumin vaccine
EP0591384A4 (de)	1995-01-18	Abgeschwächter rückmutierter virusimpfstoff gegen mareks krankheit serotyp-1.
DE60042776D1 (de)	2009-10-01	Lipoglykan zusammensetzungen und methoden zur behandlung von parasitischen infektionen
GB953992A (en)	1964-04-02	Vaccine products and method of preparing same
Greenberg et al.	1992	" Emotional disclosure about traumas and its relation to health: Effects of previous disclosure and trauma severity": Correction to Greenberg and Stone.